All In Biotech

Drug Trial Radar · NCT06842498

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Feb 22, 2026

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Kyntra BioIndustry
Sponsor type
Industry
First posted
Feb 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.

Conditions

  • Metastatic Castration-Resistant Prostate Cancer

Interventions

  • FG-3246Drug

    FG-3246 will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression-free Survival (rPFS) By Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) CriteriaTime frame: Until radiographic progression is noted (up to approximately 25 months)
  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose until 28 days after last dose (up to approximately 25 months)
  3. Maximum Plasma Concentration (Cmax) of FG-3246, Total Anti-cluster of Differentiation 46 Antibody (CD46), and Free Monomethyl Auristatin E (MMAE)Time frame: Within each 21 day treatment cycle from Cycle 1 through 28 days post last dose (up to approximately 25 months)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Western Regional Medical Center - City of Hope Phoenix Goodyear

    Goodyear, Arizona · Recruiting

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • The University of Arizona Cancer Center - North Campus

    Tucson, Arizona · Recruiting

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California · Recruiting

  • UCLA Clark Urology Center

    Los Angeles, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • New Haven Hospital - Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Bioresearch Partner - Aventura

    Aventura, Florida · Recruiting

  • Bioresearch Partner - Hialeah

    Hialeah, Florida · Recruiting

  • Biogenix Molecular, LLC

    Miami, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • East Jefferson General Hospital Metairie

    New Orleans, Louisiana · Recruiting

  • New Mexico Oncology Hematology Consultants, Ltd.

    Albuquerque, New Mexico · Recruiting

  • Duke University Medical Center - Duke Cancer Center

    Durham, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Oncology Consultants

    Houston, Texas · Recruiting

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • University of Washington Medical Center

    Seattle, Washington · Recruiting

  • Northwest Medical Specialties, PLLC - Tacoma

    Tacoma, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.